UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

Narrative Review of the Pathogenesis of Stasis Dermatitis: An Inflammatory Skin Manifestation of Venous Hypertension

Dermatology and therapy, 2023-04, Vol.13 (4), p.935-950

2023

Volltextzugriff (PDF)

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study

Journal of the American Academy of Dermatology, 2012-10, Vol.67 (4), p.642-650

2012

Volltextzugriff (PDF)

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

The Lancet (British edition), 2022-07, Vol.400 (10348), p.273-282

2022

Volltextzugriff (PDF)

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, 2023-10, Vol.37 (10), p.2041-2046

2023

Volltextzugriff (PDF)

529 - Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial

British journal of dermatology (1951), 2024-02, Vol.190 (Supplement_2), p.ii31-ii32

2024

Volltextzugriff (PDF)

Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials

Journal of rheumatology, 2016-06, Vol.43 (6), p.1063

2016

Volltextzugriff (PDF)

Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study

Journal of the European Academy of Dermatology and Venereology, 2023-10, Vol.37 (10), p.2056-2066

2023

Volltextzugriff (PDF)

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative

JAMA dermatology (Chicago, Ill.), 2022-12, Vol.158 (12), p.1429

2022

Volltextzugriff (PDF)

Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis

Allergy (Copenhagen), 2024-05, Vol.79 (5), p.1258-1270

2024

Volltextzugriff (PDF)

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Skin (Milwood, N.Y.), 2022-11, Vol.6 (6), p.s102

2022

Volltextzugriff (PDF)

Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies

Dermatitis, 2021-10, Vol.32 (1S), p.S39

2021

Volltextzugriff (PDF)

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

Dermatology and therapy, 2024-07, Vol.14 (8), p.2285-2296

2024

Volltextzugriff (PDF)

Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

Immunotherapy, 2023-09, Vol.15 (13), p.975-980

2023

Volltextzugriff (PDF)

Evaluation of Response to Ritlecitinib Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Skin (Milwood, N.Y.), 2023-03, Vol.7 (2), p.s187

2023

Volltextzugriff (PDF)

Ultraviolet B-Induced DNA Damage in Human Epidermis Is Modified by the Antioxidants Ascorbic Acid and D-α-Tocopherol

Journal of investigative dermatology, 2005-02, Vol.124 (2), p.304-307

2005

Volltextzugriff (PDF)

Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial

Dermatology (Basel), 2010-01, Vol.221 (2), p.172

2010

Volltextzugriff (PDF)

Ultraviolet B-Induced DNA Damage in Human Epidermis Is Modified by the Antioxidants Ascorbic Acid and D-[alpha]-Tocopherol

Journal of investigative dermatology, 2005-02, Vol.124 (2), p.304

2005

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(17)

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Narrative Review of the Pathogenesis of Stasis Dermatitis: An Inflammatory Skin Manifestation of Venous Hypertension

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

529 - Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial

Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials

Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative

Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

Evaluation of Response to Ritlecitinib Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Ultraviolet B-Induced DNA Damage in Human Epidermis Is Modified by the Antioxidants Ascorbic Acid and D-α-Tocopherol

Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial

Ultraviolet B-Induced DNA Damage in Human Epidermis Is Modified by the Antioxidants Ascorbic Acid and D-[alpha]-Tocopherol

Suchergebnisse filtern